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Abstract
Background: Several attempts to decipher the genetics of hypertension of unknown causes have been made
including large-scale genome-wide association analysis (GWA), but only a few genes have been identified.
Unsolved heterogeneity of the regulation of blood pressure and the shortcomings of the prevailing monogenic
approach to capture genetic effects in a polygenic condition are the main reasons for the modest results. The level
of the blood pressure is the consequence of the genotypic state of the presumably vast network of genes
involved in regulating the vascular tonus and hence the blood pressure. Recently it has been suggested that
components of the sphingolipid metabolism pathways may be of importance in vascular physiology. The basic
metabolic network of sphingolipids has been established, but the influence of genetic variations on the blood
pressure is not known. In the approach presented here the impact of genetic variations in the sphingolipid
metabolism is elucidated by a two-step procedure. First, the physiological heterogeneity of the blood pressure is
resolved by a latent class/structural equation modelling to obtain homogenous subpopulations. Second, the
genetic effects of the sphingolipid metabolism with focus on de novo synthesis of ceramide are analysed. The
model does not assume a particular genetic model, but assumes that genes operate in networks.
Results: The stratification of the study population revealed that (at least) 14 distinct subpopulations are present
with different propensity to develop hypertension. Main effects of genes in the de novo synthesis of ceramides
were rare (0.14% of all possible). However, epistasis was highly significant and prevalent amounting to
approximately 70% of all possible two-gene interactions. The phenotypic variance explained by the ceramide
synthesis network were substantial in 4 of the subpopulations amounting to more than 50% in the subpopulation
in which all subjects were hypertensive. Construction of the network using the epistatic values revealed that only
17% of the interactions detected were in the direct metabolic pathway, the remaining jumping one or more
intermediates.
Conclusions: This study established the components of the ceramide/sphingosine-1-phosphate rheostat as central
to blood pressure regulation. The results in addition confirm that epistasis is of paramount importance and is most
conspicuous in the regulation of the rheostat network. Finally, it is shown that applying a simple case-control
approach with single gene association analysis is bound to fail, short of identifying a few potential genes with
small effects.
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Hypertension, defined as office blood pressure (BP)
measurements of 140/90 mm Hg or greater, affects 30%
of the adult population, and is a major risk factor for
stroke, heart disease, and end-stage renal disease [1].
Hypertension arises as a consequence of altered activity
in signal transduction pathways and interactions of com-
plex intra- and intercellular processes [2,3]. However,
the exact mechanism and causes of hypertension are
unknown in 95% of the cases (essential hypertension).
In the remaining 5% of cases, the cause of hypertension
is secondary to various conditions including endocrine
disorders as well as drug-induced hypertension [4].
Although several clinical and biochemical variables are
correlated to hypertension [5-7] the causes of essential
hypertension remains elusive. It has been estimated that
30-60% of the blood pressure variation in humans is
caused by genetic factors [8], but so far the genetic
mechanisms underlying human essential hypertension
have not been defined [9]. Several strategies including
genome-wide association (GWA) studies [8,10,11] have
been applied, but despite these huge efforts only a few
potential genes have been associated with essential
hypertension. In particular the large GWA studies have
regrettably falling short of explaining the full genetic
picture associated with hypertension [12-16]. The rea-
sons for this are numerous, one of the most important
being that most studies do not includes gene-gene inter-
actions in the analysis (power issues being the main
cause), despite the fact that essential hypertension is a
polygenic trait influenced by an unknown number genes
probably running in the hundreds. As in all other biolo-
gical processes the regulation of the blood pressure is
defined in networks of interacting genes, in which the
activity and impact on the blood pressure depends on
the genetic variety in various parts of the networks. This
genetic variety is expressed as phenotypic heterogeneity
and essential hypertension is merely a clinical end-point
term for the diverse states of the genetic pathways of
blood pressure regulation.
Several methods have been developed to account for
population and genetic heterogeneity and epistasis [17].
The basic hypothesis is that any observable phenotype of a
complex biological system by necessity is determined by
the complexity of its underlying biochemical organisation
and the signalling network operating within it. It is the
entire network behaviour and not a single, specific variable
that determines the physiological outcome. As all bio-
chemical processes are governed by the genes encoding
for the executing proteins, the interactions of the proteins
reflect the genotype of the individual and the variations in
the genotype define the range within which the executer
operates. Thus, the entire genotype contributes to the bio-
chemical and physiological outcome and to what extent
an individual will actually develop a clinical significant
state like diabetes [17] or hypertension. Here we apply the
approach previously implemented in diabetes mellitus
type 2 to explore the genetic network of the ceramide/
sphingosine-1-phosphate (Cer/S1P) rheostat on several
measures of blood pressure in a large randomly selected
population partitioned into homogenous subpopulations
by quantitative physiological variables in a latent class/
structural equation model framework [17]. Sphingolipids
influence the vascular tone, but the effects are controver-
sial as both vasodilatory and vasoconstrictive effects have
been reported for the essential metabolites in the rheostat
network, ceramides and sphingosine-1-phosphate [18-21].
Thus, the role of the rheostat in hypertension is far from
being resolved [22]. The analysis presented here is focused
on the integrated de novo synthesis of ceramides and
extended to construct the metabolic network of the rheo-
stat. This is in contrast to the previous study on diabetes
mellitus [17] in which the genes included did not repre-
sent a composite metabolic network, but was selected
from association studies of diabetes mellitus type 2. The
structure of the Cer/S1P-rheostat network was confirmed,
but in addition it was revealed that the regulatory compo-
nents of the network are far more conspicuous than the
direct metabolic pathways.
Methods
Population
The study population is the Danish leg of the interna-
tional MONICA-study [23,24]. In brief, randomly
selected women and men from the County of Copenha-
gen were enrolled in 1982 and re-invited for a reexami-
nation in 1993-94 including 2,656 subjects [25]. Some of
the subjects only had sparse or no data on the variables
used in this study and were excluded slightly reducing
the study population to 2,523 individuals. Fasting levels
of glucose, insulin, lipids, and apolipoproteins (ApoA1,
ApoB and ApoE), C-reactive protein (CRP), B-type or
brain natriuretic peptide (BNP), soluble urokinase acti-
vator receptor (Supar), aortic pulse wave velocity (com-
pliance) and aortic stiffness (Aasi) [26] as well as
anthropometric measures as waist-hip circumference
(WH) and body mass index (BMI) were included in the
latent profile analysis LPA-SEM modelling (see below).
Insulin resistance (HOMAres) was calculated using fast-
ing glucose and insulin levels [27]. Blood pressures were
measured by a standard “office” procedure in sitting and
supine position. In addition, a 24-hr ambulatory blood
pressure monitoring was performed in a subgroup con-
sisting of 1,829 participants as described in detail else-
where [28]. At least 13 readings of systolic and diastolic
blood pressure during the day and at least 6 readings of
systolic and diastolic blood pressure during the night
were obtained. Finally, ultrasound blood pressure
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described [26]. The variables of the study population are
summarized in Table 1.
The research was performed according to the Helsinki
declaration. The study was approved by the Ethics
Committee of the Greater County of Copenhagen, Den-
mark, implying that informed consent was given by all
participants.
Model assumptions
No assumptions are made for the distribution of traits
in the basic, heterogeneous study population, but it is
assumed that the study population consists of a mixture
of more homogeneous subpopulations in which the phy-
siological variables defining and characterizing the sub-
populations are normal distributed. Variables may not
be exactly normally distributed in a tissue or an organ-
ism because of asynchrony of the dynamic processes in
the cells [29], but the maximum likelihood ratio estima-
tion method used here is robust to minor deviations
from normality (increased skewness and kurtosis)
[30,31].
All subjects are assumed to possess the same basic
genetic structures and networks, but vary in expression
because of variability in the genome, including single
nucleotide polymorphisms (SNPs), deletions, insertions,
copy-number variation, non-coding RNA complexes,
epigenetic diversity etc. No genetic structure or model is
assumed ap r i o r i , but are embedded in the latent struc-
tural equation model (SEM) as the basic network and
defines the kernel of the cellular processes. The geno-
type in individual subjects is fixed allocating an indivi-
dual to a particular subpopulation of similar
physiological expression. It is therefore implicit that no
subject transitions between subpopulations are possible.
Only transitions from one level to another level of the
blood pressure would be possible within the subpopula-
tion, depending on the load of non-genetic factors and
within the limits defined by the subpopulation-specific
genotype, i.e. the non-genetic factors operate within the
limits of a genetic framework that physiologically cannot
be exceeded.
Resolving heterogeneity in the population
The population was partitioned by an integrated latent
class/structural equation modelling (LPA-SEM) as pre-
viously described [17,32,33]. In this study it is assumed
that the population consists of a mixture of subpopula-
tions within which all variables in the model are pre-
sumed to be normally distributed (although other
distributions can be assumed) and only correlated
through the latent SEM variable as previously described
[17]. The model is schematically shown in Figure 1.
Mathematically the model is formulated as f(y|z)=
∑xπ(x|z)f(y|x, z) where we are modelling the probability
density of observing the indicators y (diastolic and sys-
tolic blood pressures) given a set of covariates z (lipids,
insulin etc.). A latent variable is interspersed between
the indicators and covariates (x, “Vasular bed” in Figure
Table 1 Summary of the indicators and covariates in the
Monica study included in the LCA-SEM analysis.
Mean (SD)
All Women Men
Number 2,523 1,257 1,266
Age 43.6 (10.8) 43.2 (10.8) 44.0 (10.7)
Blood pressure measurements (mm Hg):
Sitting systolic 129 (19) 127 (19) 132 (19)**
Sitting diastolic 82 (11) 81 (10) 84 (11)**
Supine systolic 129 (18) 127 (19) 131 (17)**
Supine diastolic 80 (10) 78 (10) 82 (10)**
Day systolic 131 (14) 127 (14) 134 (13)**
Day diastolic 78 (10) 75 (10) 81 (9)**
Night systolic 112 (14) 110 (15) 115 (14)**
Night diastolic 64 (9) 62 (9) 66 (9)**
24 hour systolic 126 (14) 123 (14) 129 (13)**
24 hour diastolic 74 (9) 71 (9) 77 (9)**
Ultrasound left site systolic 131 (21) 130 (22) 132 (19)**
Ultrasound left site diastolic 79 (11) 78 (12) 81 (11)**
Ultrasound right site
systolic
127 (21) 126 (22) 128 (19)*
Ultrasound right site
diastolic
78 (11) 77 (11) 80 (11)**
Ultrasound mean systolic 129 (20) 128 (21) 130 (18)*
Ultrasound mean diastolic 79 (11) 77 (11) 80 (10)**
Total cholesterol (mmol/L) 6.2 (1.1) 6.1 (1.1) 6.2 (1.1)
LDL cholesterol (mmol/L) 4.0 (1.0) 3.9 (1.0) 4.1 (1.0)**
VLDL cholesterol (mmol/L) 0.65 (0.37) 0.58 (0.29) 0.72 (0.42)**
T riglycerides (mmol/L) 1.46 (1.04) 1.29 (0.88) 1.63 (1.16)**
HDL cholesterol (mmol/L) 1.44 (0.41) 1.60 (0.43) 1.29 (0.34)**
WH ratio 0.88 (0.09) 0.82 (0.06) 0.94 (0.06)**
BMI (kg/height
2) 26.0 (4.2) 25.4 (4.5) 26.5 (3.8)**
Insulin (pmol/L) 38 (33) 33.5 (26.4) 42 (38)**
Glucose (mol/L) 4.9 (1.1) 4.7 (0.9) 5.1 (1.2)**
HOMAres 1.46 (1.73) 1.24 (1.22) 1.69 (2.10)**
ApoA1 (mmol/L) 52.6 (21.4) 56.0 (22.6) 49.6 (20.0)**
ApoB (mmol/L) 0.73 (0.24) 0.70 (0.24) 0.77 (0.24)**
ApoE (mmol/L) 2.25 (1.18) 2.30 (1.23) 2.20 (1.13)*
Compliance 0.57 (0.15) 0.59 (0.15) 0.55 (0.15)**
Aasi 11.1 (3.3) 10.6 (3.3) 11.6 (3.3)**
Left ventricular mass 80.5 (21.1) 73.2 (17.5) 88.0 (21.7)**
Supar (mg/L 4.21(1.33) 4.39 (1.31) 4.01 (1.32)**
BNP (ng/L) 76.0
(135.1)
89.5
(115.7)
61.7 (152.2)
**
CRP (mg/L) 3.2 (5.5) 3.4 (6.1) 3.1 (5.0)
Day, Night and 24 hour blood pressures are mean of several measurements
dyring the time period.
*p < 0.01; **p < 0.001 (difference between gender).
Fenger et al. BMC Genetics 2011, 12:44
http://www.biomedcentral.com/1471-2156/12/44
Page 3 of 181) i.e. the indicators are not directly regressed on the
covariates. The latent SEM variable is a composite vari-
able as it includes a plethora of processes that are not
measured directly. As such, all distinct processes defined
in small integrated networks are latent, but at the
moment we are only modelling a summary latent vari-
able consisting of an ensemble of (often undefined)
membrane composition, organelles, signalling and regu-
latory pathways, genetic structures and variations, and
any biochemical processes that are involved in the viabi-
lity and dynamic behaviour of the cell. In this formula-
tion π(x|z) is the probability of having a certain set of
values for the discrete latent variable (x) given an indivi-
dual’s observed covariates. The conditional π(x|z)i s
equivalent to the probability for an individual to belong
to a subpopulation and sums to 1 over all subpopula-
tions for each subject. At the population level, π(x|z)
reflects the relative size of a subpopulation.
The outcome of this modelling is a classification of
the population sample in mutually exclusive subpopula-
tions with significantly distinct physiological states
differing in their propensity to evolve into the clinical
endpoint hypertension. However, the clinical endpoint
per se was not entered in the model. Analysis were per-
formed using Mplus v 5.1 [30] attempting to obtain nor-
mal distributions of the variables and using the adjusted
Bayesian information criteria (BIC) as the goodness-of
fit measure and the entropy as defined in the pro-
gramme as a measure of accuracy of the partitions. BIC
evaluates the likelihood of the model compared to the
null-model and corrects for sample size. The model
w i t ht h el o w e s tB I Cv a l u ei sc o n s i d e r e dt h em o d e lo f
choice. If two (or more models) are equivalent or only
marginal different the entropy as a measure of the
errors in the models provide guidance of which model
to select (see Results for evaluation of the models).
Genotyping
The entire study population was genotyped for single
nucleotide polymorphisms (SNPs) related to the de novo
synthesis of ceramides and the kernel of the ceramide/
spingosine-1-phosphate rheostat. Many more genes are
Figure 1 The figure illustrates the simplified blood pressure model. The centre of the model is the latent “Vascular bed”, which is in
quotation mark as it represent a latent structure harboring all kinds of metabolic, physiologic and genetic processes in the arterial vessels. The
physiological state of the vascular bed govern the diastolic and systolic blood pressures, which are the indicators in the model. The physiological
state of the arterial vessels are influenced by several covariates as indicated in the figure. The covariates Apolipoproteins, Lipids, Antropometric,
and Inflammatory covers several items each, but are not shown separately (see the text for details). Insulin and glucose is the variables used to
calculate insulin resistance (HOMAres), but is not shown here as the measure is partly an intrinsic parameter in the vascular cells as well as many
other tissues.
Fenger et al. BMC Genetics 2011, 12:44
http://www.biomedcentral.com/1471-2156/12/44
Page 4 of 18involved in the sphingolipid metabolism, many of which
we have none or only limited knowledge about. There-
fore the focus of this study was restricted to the well-
described basic metabolism of ceramides and sphingo-
sine-1-phosphate (see Figure 2). Missense or frameshift
mutations in all exons in the selected genes were
included in the genetic analysis. For exons in which no
missense mutations are present synonymous mutations
were genotyped to obtain maximum coverage of the
genes. The details of the genes and SNPs are listed in
Tables T1 and T2 (see Additional files 1 and 2). The
genotyping was performed by KBioscience, Hoddesdon,
UK. Genotyping was validated in 5% of the population
for all genes and all genotypes were confirmed. Missing
genotypes were in the range 0.07% to 3.4% (mean 0.88%,
median 0.84%). No imputations of missing genotypes
were attempted.
Epistasis and network constructions
The rheostat network was re-constructed using variance
decomposition of two-SNP interactions. The SNP-SNP/
gene-gene interactions (epistasis) and heritabilities were
calculated as described [17,34]. Briefly, the procedure
described by Lynch and Walsh [34] is a simple step-wise
decomposition of genetic values and effects used to cal-
culate variances. Single SNP additive and dominance
variance as well as two-SNP additive-additive, additive-
dominant and dominant-dominant variance are calcu-
lated. The variance decomposition in these formulations
was orthogonal [35,36], that is the estimates obtained
are consistent and unbiased provided Hardy-Weinberg
equilibrium holds. Tests for significance is described in
[17] and references therein where corrections of flaws in
the original procedures have been corrected.
All algorithms were encoded in R and run in a Python
shell in Linux (Ubuntu v. 9.4).
The LPA-SEM partition using blood pressure mea-
surements in the supine position as indicators was used
in network construction as this partition generated the
best fitting model (see Results). Significant genetic var-
iances of the supine diastolic and systolic blood pressure
measurements were used to select subsets of two-SNP/
gene interactions in the construction of the network, i.e.
the fraction of epistatic variances relative to total pheno-
typic variance represented the links and the proteins
(enzymes) constituted the nodes in the network.
Figure 2 Schematic outline of the ceramide/sphingosine-1-phosphate rheostat.S i n g l ea r r o w si n d i c a t ei r r e v e r s i b l ep r o c e s s e s ,i . e .n o
enzymatic activities have been detected that reverses the metabolic pathway depicted by the arrows. Of particular interest is the degradation of
sphingosine-1-phosphate to hexadcanal and phophoethanolamine which is a sink for sphingosine-1-phosphate irreversibly terminating its
signalling activity.
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stress, Katz and vitality) were calculated as summarized
in Junker et al [37]. Calculations and network construc-
tions were performed using the CentriBiN [37] and
Pajek [38] softwares. Linkage disequilibrium and haplo-
type inference were performed using the Arlequin soft-
ware [39].
Statistics
All basic statistics were performed in SPSS v18.0. Bon-
feroni correction for multiple testing with a nominal p-
value of 0.05 was applied to all analysis. In the final
model with 14 subpopulations the cut-off p-value is
2*10
-6. This value may differ slightly in the other models
depending on the number of subpopulations defined.
The Linux R-front-end RKWard http://rkward.source-
forge.net was implemented in tests for normality of the
variables [40].
Results
The distribution of the diastolic and systolic blood pres-
sures and all the co-variates entering the partition mod-
els except Aasi were significantly non-normal in the
overall population (see Additional file 3). Using the Sha-
piro-Wilk test for normality of Aasi suggested that this
variable is non-normally distributed with a p-value of
4.4*10
-3, but was normal distributed when other tests
for normality were used (Lilliefors/Kolmogorov-Smirnov
and Anderson-Darling [40]). Thus, the study population
is extremely heterogeneous suggesting that the popula-
tion is composed of a mixture of physiological different
subpopulations.
Resolving heterogeneity in the population
The covariates significantly influencing the LPA-SEM
classification includes measures for insulin-glucose
metabolism (HomaRes, waist-hip ratio), lipid metabo-
lism (VLDL, apolipoprotein A1, B, and E), markers for
low-grade inflammatory disease (C-reactive protein
(CRP), soluble urokinase activator receptor (Supar),
brain natriuretic peptide (BNP)), and measures of vessel
stiffness (compliance, Aasi). Most of these entered as
covariates in the seven models in the LPA-SEM parti-
tions, but may vary in rank (Table 2). VLDL was
included in all models and is particularly interesting as
it and other lipoproteins are composite particle harbour-
ing ceramides and sphingosine-1-phosphate [41,42]. The
entropy measures indicated a rather high, although not
complete, accuracy of the partitions.
A basic assumption in the modelling is that the popu-
lation is composed of a mixture of normally distributed
subpopulations. The purpose of the LPA analysis was to
disentangle the physiological heterogeneity of the popu-
lation and to define more homogeneous subpopulations
(i.e. defining more precise phenotypes) and this was
obtained to a large extent (Table 2). Disregarding the
inflammatory markers BNP and CRP, which are rather
non-specific variables and had extremely high variance
or standard errors (Table 1), the fraction of normalized
traits increased up to 80%. Most notably, the indicators
in the models (the blood pressure measurements) were
all normalized without exception. This was not the case
for the models without covariates, where 4 of the 7
models did not normalize the indicators. Comparison of
the models with and without covariates included
revealed a small, but significant influence on the error
structure of the co-variates indicated by the modest
changes of the entropy measure (Table 2). However,
inclusion of the co-variates reduced the adjusted BIC
values approximately 25% (not shown). Thus, the indica-
tors imposed the most weight on the basic partition,
while the covariates improved the goodness-of-fit of the
model, and normalized the indicators fulfilling a major
assumption in the LPA-SEM model. The distributions
of the covariates were generally “uniform” and did not
have any predictive value to the assignment of subjects
to the subpopulations. The analysis of models without
the co-variates i.e. a pure finite mixture model [33]
revealed a significantly different distribution of the sub-
jects between the subpopulations than the models
including the covariates (p < 0.001). This is shown for t
blood pressure measured in supine position (the Supine
model) in Table 3. The distribution was more “uniform”
for the models including covariates and in all models
the highest and lowest numbers of subjects in the sub-
populations were assigned in the pure finite mixture
models.
The indicators were strongly correlated for all the dif-
ferent measures of blood pressure (p < 0.001). The mod-
elling approach tries to explain the correlation between
the indicators by a common latent variable, that is, cor-
relation between observed variables should vanish in a
perfect classification. Indeed, the correlations between
the indicators (diastolic and systolic blood pressure) in
the subpopulations in each model were non-significant
to a large extent except for the UL2 model (Table 2).
Most of the classes with correlated indicators are large
suggesting that heterogeneity has not been resolved in
these classes. In a few classes with correlated indicators
the number of subjects was in the low end suggesting
either that the models were overfitted or that (unknown)
covariates of importance were not included. Only the
Supine model provided non-correlation between the
indicators in all the classes. In this model without
including the covariates the diastolic and systolic blood
pressures were correlated in 5 of the 14 subpopulations
indicating that modelling pure finite mixture models
was insufficient and produced incorrect results.
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nificantly between the subpopulation in each model and
reached 100% in most of the models the exceptions
being the Night and UL2 models (se Additional file 4).
Taken together the above results suggest that the Supine
model provides the most accurate description of the popu-
lation and this model will be the benchmark model in the
following. It should remembered that decisions about
which model is the “best” in LPA.-SEM procedures may
be subtle. It could be argued that some of the other mod-
els may be “better” or at least “as good”.T h eS u p i n e
model is, however, one of the best models fulfilling most
criteria and assumptions in the LPA-SEM approach in
particular a high entropy and non-correlations of the indi-
cators. A practical argument for focusing on the Supine
model is that supine blood pressure measurements are
readily available, which make the further analysis of the
Supine model more appropriate to future studies.
The distribution of subjects in the 14 subpopulations
in the Supine model is shown in Figure 3. Similar pat-
terns were obtained for all the other models in Table 2
(not shown). The distribution of the subjects in the sub-
populations can be viewed in Figure F1 (see Additional
file 5) together with basic statistical measures. Assign-
ment of subjects to subpopulations differed significantly
between the models suggesting that the mode of blood
pressure measurements reflects differences in physiology
(e.g. sitting versus supine) and/or differences in techni-
ques (e.g. sphygmanometer versus ultrasound).
Genetic analysis
The focus in this study was the de novo synthesis path-
way of ceramides, and comprehensive coverage was
attempted for this part of the rheostat network. The
selected genes and single nucleotide polymorphisms
(SNPs) included are listed in Tables T1 and T2 (see
Additional files 1 and 2). The SNPs were extracted from
dbSNP database (NCBI) as of March 2009. Genotyping
of five of the 106 SNPs was unsuccessful despite several
attempts to genotype them. In addition, 56 of the SNPs
turned out to be monomorphic and thus were non-
informative. The remaining 45 SNPs were informative
a n di n c l u d e di nt h eg e n e t i ca n a l y s e s .T h en u m b e ro f
possible two-SNP interactions is thus 990, which are
evaluated in all subpopulations for all the modes of
blood pressure measurements.
Most of the genes were represented by more than one
SNP. Several of the SNPs in the same gene were in link-
age disequilibrium (LD) (se Additional file 2). However,
50% of the possible intragenic linkage disequilibria were
not detected. The intergenic LDs amounted to 4.11% of
all possible, despite that all the genes are located on dif-
ferent chromosomes. In the Supine subpopulations
(which are the show-case of this presentation) the intra-
genic LDs were in the range of 2.5-42.5%, while the inter-
genic LDs were reduced in the most of the
subpopulations (range 0 - 4.21%). All SNPs except
rs41303970 and rs7302981 were in Hardy-Weinberg
equilibrium in the study population. This may be due to
Table 2 Summary of the LCA-SEM partition using systolic and diastolic blood pressure as indicators
Entropy
b
Model Number of
subpopulations
Co-variates in decreasing order of
significans
a
With
covariates
Change %
Normalized
d
Correlation of
indicators
e
Excluding CRP and BNP
Average 24
hours
14 CRP HomaRes Compliance Supar VLDL Aasi
WH BNP ApoE
0.789 -2.3% 66.9% 81.8% 71.4%
Average
daytime
12 CRP HomaRes Compliance Supar VLDL WH
BNP ApoE Aasi ApoA1
0.788 +5.3% 61.1% 75.0% 83.3%
Average
night
13 CRP HomaRes Compliance Supar VLDL BNP
ApoE
0.747 -9.3% 64.1% 79.5% 84.6%
Sitting
(office BP)
11 CRP Compliance VLDL Homares Age BNP BMI
ApoA1
0.724 -1.0% 50.0% 69.1% 81.8%
Supine 14 HomaRes BNP Compliance Supar VLDL CRP
Age BMI ApoA1
0.792 +2.5% 68.8% 80.5% 100.0%
UL4
c 12 HomaRes CRP Supar BNP VLDL ApoA1 ApoE 0.759 -5.8% 47.0% 65.2% 80.6%
UL2
c 14 HomaRes BNP Compliance Supar VLDL CRP
ApoA1 Age BMI
0.801 +5.8% 68.7% 80.8% 28.6%
a CRP, C-reactive protein; HomaRes, insulin resistance;VLDL, very low densitity lipoprotein; Aasi, vessel stifness; WH, waist-hip ratio; BNP, B-type or brain natriuretic
peptide; BMI, body mass index; Apo, apolipoprotein; Supar, soluble urokinase activator receptor.
b Entropy for the full model as defined in the MPlus programme (1 - standard entropy) for the error structure. Changes signifies deviation from the model
without covariates.
c Ultrasound recording of systolic and diatolic blood pressure: UL4, left and rigth measurements are seperate indicators;
UL2, average of left and right systelic and diastolic blood pressure, respectively, are used as indicators
d Fraction of traits in all classes normalized by the LCA-SEM partition. Only the traits listed and the mode of blood pressure measurements are included in the
calculation
e Fraction of indicators not correalted after LCA-SEM partition
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lent quality (see Methods) it isn o tal i k e l ye x p l a n a t i o n .
Rather, the two exceptions may reflect that the study
population consisted of a mixture of subpopulations in
which the SNPs may or may not be in Hardy-Weinberg
equilibrium. Therefore, all SNPs are included in the ana-
lysis of all the subpopulations, but any SNP not in equili-
brium were excluded from variance decomposition
analysis. This will be the case for all SNPs not just the
two SNPs not in equilibrium in the general study
Table 3 Number of significant interactions in the subpopulations in the Supine model
Partition: model with
covariates
Supine model without
covariates
Trait: Systolic Diastolic Systolic Diastolic
Subpopulations No
cases
Interactions Fraction Interactions Fraction No
cases
Interactions Fraction Interactions Fraction
1 39 307 32,49% 307 32,49% 27 331 35,03% 306 32,38%
2 111 318 33,65% 316 33,44% 113 325 34,39% 325 34,39%
3 259 298 31,53% 294 31,11% 625 323 34,18% 335 35,45%
4 33 230 24,34% 334 35,34% 104 338 35,77% 338 35,77%
5 189 257 27,20% 257 27,20% 1 0 0,00% 0 0,00%
6 301 321 33,97% 310 32,80% 30 320 33,86% 320 33,86%
7 132 306 32,38% 307 32,49% 23 262 27,72% 332 35,13%
8 89 238 25,19% 238 25,19% 89 304 32,17% 305 32,28%
9 237 275 29,10% 276 29,21% 332 231 24,44% 238 25,19%
10 141 334 35,34% 337 35,66% 279 295 31,22% 295 31,22%
11 163 295 31,22% 302 31,96% 7 0 0,00% 0 0,00%
12 40 336 35,56% 336 35,56% 544 226 23,92% 232 24,55%
13 166 307 32,49% 306 32,38% 73 285 30,16% 285 30,16%
32,28%
14 21 174 18,41% 148 15,66% 19 159 16,83% 305
Sum 1.921 3.996 4.068 2.266 3.399 3.616
Average 285,43 30,20% 290,57 30,75% 242,79 25,69% 258,29 27,33%
Variance 2.115 2.498 13.074 13.012
Average Total 30,20% 30,75% 25,69% 27,33%
Minimum 21 174 18,41% 148 15,66% 1 0 0,00% 0 0,00%
Maximum 301 336 35,56% 337 35,66% 625 338 35,77% 338 35,77%
Systolic versus diatolic blood pressure
b Number of interactions Number of interactions
p-value 0,78 0,72
Supine model with and without
covariates
c
Systolic Diastolic
F-test p-value 0,0024 0,0055
Number of total
interactions detected
Full model Model without
co-variates
Interactions Fraction Interactions Fraction
Systolic 676 68,28% 695 70,20%
Diastolic 681 68,79% 695 70,20%
a The fraction is calculated as the number of significant interactions detected realtive to the maximal number of interaction possible
b Test of difference in number of interactions between diastolic and systolic blood pressures
c Test of the number of significant interactions in the two models. The number of interactions in the model with covariates (the fulle model)
is significant higher than in the resticted model without covariates.
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subpopulations.
Intragenic interactions could be caused by physical
linkage (LD) or because the partition by the LPA-SEM
procedure group variants defining the physiological state
(blood pressure). The interaction analysis cannot discern
between these two possibilities and therefore the intra-
genic SNPs were disregarded in the further analysis of
epistasis or represented by the SNP with the largest
interactions with other genes in the centrality and net-
work analysis (see below).
Gender partition
Although gender represents a rather crude partition of a
study population it served the purpose of providing an
overall view of the genetic structure of the Cer/S1P
rheostat related to blood pressure. Two-locus interac-
tions were evaluated for all modes of diastolic and systo-
lic blood pressure measurements. Approximately one
third of the possible number of interactions (990 for
each mode of blood pressure measurements and each
gender) were significant in men and slightly more in
women (see Additional file 6). The SNP-combinations
differed among the models summing the total number
of significant epistasis to slightly above half the possible
number of interactions. Except for 11 interactions all
the common interactions in systolic and diastolic blood
pressure were the same (not shown). None of the genes
showed any main effects (adjusted p-value <5.1e-05),
but all the genes participated significantly in various and
numerous interactions, although the phenotypic var-
iances accounted for were very small for each two-gene
interactions (average 0.001 and less than 0.012).
LPA-SEM partitions
The LPA-SEM partition significantly reduced the var-
i a n c eo ft h eb l o o dp r e s s u r e sa ss h o w nf o rt h eS u p i n e
model in Table T6 (Additional file 7). The number of
possible epistatic interactions were 990 for the 45 SNPs
included, but the actual number of interactions were less
and varied between models and subpopulations as the
partitions left SNPs monomorphic in some of the subpo-
pulations and because in some cases the traits (blood
pressures or covariates) were missing (see Additional files
Figure 3 Partition of the population into 14 subpopulations using the supine blood pressure measurements as indicators and
including the covariates in LPA-SEM procedure. The figure shows the distribution of the 14 subpopulations and the overall statistics of the
study population. Similar distributions were obtained in the other models. A view of the subpopulations in the Supine model can be seen in
Additional file 5.
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Page 9 of 188 and 9). In subpopulations with less than 30 subjects
only two subpopulations failedt od e t e c ta n ys u b s t a n t i a l
interaction: in the subpopulation with 6 subjects (the
Night model, subpopulation 1, not shown) no interactions
were detected; and in the subpopulation with 22 subjects
(the UL2 model subpopulation 2, not shown), only one
interaction where detected (between rs455225532 in
CerS1 and rs17160349 in CerS4). The latter could be
interpreted as a false positive result, but the genetic var-
iance accounted for was 14.3% of the phenotypic variance,
and this SNP-combination was detected in numerous
other models and subpopulations, hence the interaction
was most probably real.
No interactions could be detected for four of the SNPs
in any of the models with co-variates (see Additional files
8 and 9). These were rs10103355 (ASAH1), rs2066509
(GCLC), rs10122075 (ACER2), and rs9306515 (CERKa),
although the latter did reveal one interaction for diastolic
blood pressure in the Supine model. However, in contrast
to rs10103355 and rs2066509 the latter two SNPs only
had one and two heterozygous genotypes in the entire
population, respectively (see Additional file 2). All other
subjects were homozygous for one of the genotypes. The
number of interactions each SNPs participated in varied
widely, the minimum being zero and the maximum 68%
of all possible interactions. The maximum number of
interactions in one or more of the subpopulations in all
models for all SNPs varied but on average approximately
half of possible interactions were detected and over 80%
were detected in some subpopulations (see Additional files
8 and 9). I.e. the SNP-SNP interactions (and hence gene-
gene interactions) were extensive and varied between
models and between subpopulations within models.
The single SPTLC1 SNP (rs45461899) had 37 interac-
tions (0.2% of all possible interaction) in the Supine and
UL2 models (18 and 19, respectively) but none in the
other models. In both models the interactions were only
found in one subpopulation (14 and 10, respectively)
and the number of interactions ranged from 8.9% to
20.0% of all possible interactions in these two subpopu-
lations and hence the SNP do probably influence the
blood pressure in these subpopulations.
In summary, the above observations suggest that mod-
els with low or no interactions in one or several subpo-
pulations were less reliable. In addition, the lesser
goodness-of-fit of models with small numbers of sub-
jects in one or more subpopulations, which were parti-
cularly prominent in models with no covariates included
(not shown), suggests that such models should be con-
sidered with caution.
The Supine model
The distribution of cases in subpopulations and the
number of interactions is summarized in Table 3 for the
Supine model with and without covariates included in
the LPA-SEM procedure (for a graphical view see Addi-
tional file 5). On average ~30% of all possible interac-
tions were detected after correction for multiple testing
in the model including covariates and a little less in the
model without covariates included. There were no dif-
ferences in the number of interactions between systolic
and diastolic blood pressure, but there was a significant
difference in the distribution of interactions between
models with and without covariates included in the
models.
The relative genetic variance in the subpopulations of
the Supine model is summarized in Table 4. Almost 700
of the 990 (~70%) possible interactions were detected in
one or more subpopulations. The interactions were on
average detected in 6 subpopulations. A few differences
were present for the two blood pressure traits: four
interactions for the diastolic blood pressure were not
found for the systolic blood pressure; and nine interac-
tions for the systolic blood pressure were not found for
the diastolic blood pressure (see Additional file 10).
Interestingly, all of these were exclusively present in
subpopulation 14, the hypertensive subpopulation par
excellence (Table 4).
Six SNP-interactions were detected in all the subpopu-
lations for diastolic blood pressure (see Additional file
11). Three of these were also present in all the systolic
blood pressure subpopulations, while the other three
were detected in all the subpopulations less one. The
interactions with the maximum values were exactly the
same for the two blood pressure measurements and
were almost the same in the subpopulations. These
interactions identified some of the components of the
rheostat, but details of the identified pathway were miss-
ing. For instance, sphingosine-1-kinase 1 (SPHK1) was
not detected which would be the “missing link” between
the ceramidases and the SP-1 lyase. Including all inter-
actions detected in at least 13 of the 14 subpopulations
captured SPHK1 and in particular placed the enzyme in
the right position of the network (see Additional file
12). Some of the genes with more than one entrance dif-
fered in the influence of their SNPs depending on the
subpopulation. However, none of the maximum genetic
variances were captured by restricting the analysis to
the most common interactions.
Unique interactions were detected in 5 of the 14 sub-
populations amounting to almost 9% of all possible
interactions (see Additional file 13). The maximal rela-
tive genetic variance was detected for the interaction
between rs243887 (SPTLC3) and rs17159388 (CerS4)
and amounts to 52% of the phenotypic variance in sub-
population 14. Two of the genes (SPTLC3 and CERKa)
were only involved in interactions for diastolic blood
pressure, and 4 genes (SPHK1, SPHKAP, SGPL1, and
Fenger et al. BMC Genetics 2011, 12:44
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Page 10 of 18Table 4 Summary of epistasis and the hypertensive state in the Supine model
Subpopulation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Entire
population
Number of subjects 39 111 259 33 189 300 132 89 237 141 163 40 166 21
Genetics
Diastolic blood pressures
Number of interactions 307 316 294 334 257 310 307 238 276 337 302 336 306 148 676
Percentage of possible (990) 31,0% 31,9% 29,7% 33,7% 26,0% 31,3% 31,0% 24,0% 27,9% 34,0% 30,5% 33,9% 30,9% 14,9% 71,5%
Number of interactions
curated
3
101 136 126 120 111 142 130 114 119 140 143 119 121 94
Percentage of possible (253) 39,9% 53,8% 49,8% 47,4% 43,9% 56,1% 51,4% 45,1% 47,0% 55,3% 56,5% 47,0% 47,8% 37,2%
Genetic values
b:
Average 0,0338 0,0069 0,0032 0,0430 0,0049 0,0021 0,0059 0,0102 0,0031 0,0057 0,0039 0,0244 0,0049 0,1532
Median 0,0260 0,0060 0,0020 0,0233 0,0032 0,0014 0,0040 0,0077 0,0022 0,0041 0,0032 0,0180 0,0037 0,1081
Maximum 0,1689 0,0322 0,0191 0,3166 0,0285 0,0107 0,0371 0,0472 0,0182 0,0283 0,0214 0,1359 0,0259 0,5209
Minimum 0,0022 0,0003 0,0000 0,0029 0,0000 0,0001 0,0002 0,0002 0,0001 0,0002 0,0001 0,0015 0,0001 0,0099
Systolic blood pressures
Number of interactions 307 318 298 230 257 321 306 238 275 334 295 336 307 174 681
Percentage of possible (990) 31,0% 32,1% 30,1% 23,2% 26,0% 32,4% 30,9% 24,0% 27,8% 33,7% 29,8% 33,9% 31,0% 17,6% 68,8%
Number of interactions
curated
a
102 136 128 104 111 144 130 114 120 141 143 119 122 103
Percentage of possible (253) 40,3% 53,8% 50,6% 41,1% 43,9% 56,9% 51,4% 45,1% 47,4% 55,7% 56,5% 47,0% 48,2% 40,7%
Genetic values:
Average 0,0334 0,0069 0,0032 0,0468 0,0049 0,0021 0,0060 0,0103 0,0031 0,0058 0,0040 0,0244 0,0048 0,1663
Median 0,0257 0,0059 0,0020 0,0335 0,0032 0,0014 0,0040 0,0077 0,0023 0,0042 0,0033 0,0180 0,0035 0,1116
Maximum 0,1687 0,0321 0,0192 0,3208 0,0285 0,0108 0,0372 0,0472 0,0183 0,0283 0,0214 0,1360 0,0260 0,5209
Minimum 0,0021 0,0002 0,0000 0,0052 0,0001 0,0001 0,0002 0,0004 0,0001 0,0001 0,0001 0,0015 0,0002 0,0089
Blood pressures
Diastolic blood pressures
Mean 60,0 69,9 68,3 71,5 82,9 75,2 89,5 79,7 88,3 79,1 95,6 86,2 78,6 112,6 80,1
Std. Deviation 4,2 4,1 3,5 4,0 2,1 2,2 6,9 1,5 3,3 2,8 5,0 2,0 6,1 8,2 10,1
Std. Error 0,7 0,4 0,2 0,8 0,2 0,1 0,6 0,2 0,2 0,2 0,4 0,3 0,5 1,8 0,2
Lower Bound (95%
CI)
58,6 69,1 67,9 69,8 82,6 75,0 88,3 79,4 87,9 78,6 94,8 85,5 77,7 108.9 79,7
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8Table 4 Summary of epistasis and the hypertensive state in the Supine model (Continued)
Upper Bound (95%
CI)
61,4 70,7 68,8 73.2 83,2 75,5 90,7 80,0 88,7 79,5 96,4 86,8 79,5 116,3 80,6
Minimum 49,5 60,5 58,5 63,0 78,0 69,5 73,5 76,5 79,0 70,5 81,0 82,0 62,0 98,0 49,5
Maximum 69,0 79,5 79,0 79,5 89,5 81,0 107,5 84,0 97,5 84,5 108,5 91,0 92,5 132,5 132,5
Systolic blood pressures
Mean 97,8 118,1 109,2 117,0 123,8 118,3 159,0 119,3 133,9 132,8 152,3 139,4 138,5 182,5 128,8
Std. Deviation 4,6 6,1 5,3 11,9 4,7 5,5 13,3 5,0 6,1 6,9 10,4 3,7 8,9 12,3 17,8
Std. Error 0,7 0,6 0,3 2,1 0,3 0,3 1,2 0,5 0,4 0,6 0,8 0,6 0,7 2,7 0,4
Lower Bound (95%
CI)
96,3 117,0 108,5 112,8 123,2 117,7 156,7 118,3 133,2 131,7 150,7 138.3 137,1 177,0 128,0
Upper Bound (95%
CI)
99,3 119,3 109,8 121.2 124,5 118,9 161,3 120,4 134,7 134,0 153,9 140,6 139,8 188.1 129,6
Minimum 84,5 99,0 93,5 96,51 108,0 98,0 122,0 106,5 111,0 117,5 105.5 132,5 116,0 158,5 84,5
Maximum 105,5 130,5 124,0 139,5 135,5 132,5 189,0 131,5 147,0 150,5 179,5 148.0 162,0 211,0 211,0
Hypertensive subjects (%)
Diastolic 0 00 0 0 0 47,7 0 16 16,3 88,3 42,5 42,2 100
Systolic 0 00 0 0 0 91,7 0 25,7 0 87,1 2,5 1,2 100
Distribution of age groups
1 82,1 1,8 62,5 21,2 43,9 49,8 0,0 61,8 35,9 1,4 11,0 2,5 0,0 19,0
2 17,9 9,9 30,1 18,2 45,0 37,2 5,3 34,8 43,0 22,7 39,3 20,0 0,5 47,6
3 0,0 61,3 7,4 42.4 11,1 12,3 31,8 3,4 20,7 61,7 38,7 57,5 24,7 33,3
4 0,0 27,0 0,0 18,2 0,0 0,3 62,9 0,0 0,4 14,2 11,0 20,0 74,7 0,0
Distribution of hypertensive subjects in age groups
1 Diastolic 0 00 0 0 0 0 0 34,1 0 88,9 0 0 100
Systolic 0 00 0 0 0 0 0 18,8 50 83,2 0 0 100
2 Diastolic 0 00 0 0 0 57,1 0 32,4 0 96,9 0 0 100
Systolic 0 00 0 0 0 100 0 15,7 31,2 90,6 62,5 0 100
3 Diastolic 0 00 0 0 0 52,4 0 28,6 0 84,1 0 0 100
Systolic 0 00 0 0 0 85,7 0 26,5 13,8 93,7 34,8 58,5 100
4 Diastolic 0 00 0 0 0 48,2 0 0 0 66,7 25 1,6 100
Systolic 0 00 0 0 0 96,4 0 0 0 88,9 50 41,3 100
a Restricted to one interaction per gene-pair
b Relative gene tic variance of phenotypic variance
The subpopulations in bold have relative genetic variance above 0.05.
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8GLCM) were only detected for systolic blood pressure.
However, genetic variations in these genes did not
define any subpopulations unambiguously.
T h en u m b e ro fi n t e r a c t i o n s ,t h es i z eo ft h er e l a t i v e
genetic variance and distribution of hypertensive sub-
jects in the subpopulations are summarised in Table 4.
Four of these had relative genetic variance above 0.1
(subpopulations 1, 4, 12, and 14), while the remaining
subpopulations had values below 0.05. No hypertensive
subjects were detected in subpopulation 1 and 4, while
all the subjects were hypertensive in subpopulation 14
regardless of age. In subpopulation 12 almost 50% of
the subjects were hypertensive and they tend to be in
t h eo l d e ra g eg r o u p s .T h e s ef o u rs u b p o p u l a t i o n s
amounted to 6.9% of the entire populations and 10.1%
of the diastolic hypertensive and 6.3% of the systolic
hypertensive subjects.
Calculation of single SNP heritabilities i.e. relative
additive + dominant variance[ 3 3 ]o n l yr e v e a l e dat o t a l
of 21 SNPs in 10 genes restricted to 5 subpopulations
with heritabilities above 0.01 (see Additional file 14),
that is only 0.14% of all possible main effects for single
SNPs were detected. In subpopulation 14 exclusively
consisting of hypertensive subjects nine SNPs had sub-
stantial heritabilities, though several of the genes in the
kernel (in particular SPHK1) did not show any heritabil-
ities above 0.01.
I nt h ee n t i r ep o p u l a t i o n1 2 . 1 %o ft h es u b j e c t sh a da
diastolic blood pressure above 90 mmHg, 18.0% of the
subjects had a systolic blood pressure above 140 mmHg,
and 8.8% of the subjects had blood pressures above both
thresholds. In a case-control design using these defini-
tions of hypertension the maximal single-gene heritabil-
ities did not exceed 0.0034 and were all represented by
the same three SNPs in ACER1, ACER2, and CERKa.
The numbers of significant epistasis were substantially
lower than in the Supine model amounting to 55.25% of
all possible epistasis. The maximal relative genetic var-
iance (epistasis) was 0.0172, again substantially lower
than in any subpopulation in the Supine model.
Networks
Sixteen of the 23 genes were connected in all subpopu-
lations with a few exceptions, while the remaining 7
only connected to various degrees in all the subpopula-
tions in the Supine model (see Additional files 15 and
16). Some of the latter genes signified differences of
importance in some of the sub-pathways in the rheostat.
This was most pronounced by the ceramide synthases,
which differs in substrate specificity [43]. The rheostat
network from subpopulation 14, the diastolic blood
pressure, omitting all intragenic interactions (possible
LDs), was the most simple and most comprehensive of
all the subpopulation networks (see Additional file 17).
The network contains 94 links (37.2% of all possible),
but 3 genes were not connected at all (CerS1, CerS6,
and ELOV3). A few more connections were present in
the systolic network (not shown), but the same genes
were captured (and missed). In particular, the rate-limit-
ing enzyme SPTLC3 were connected in all networks,
but the analogue SPTLC1 was only connected in subpo-
pulation 14.
Subpopulations 1 and 14 represent the most non-
hypertensive and the most hypertensive subpopulations,
respectively. Although most links are present in both
subpopulations networks it was clear that there were
substantial and complex difference between the subpo-
pulations of their connections in the rheostat network.
Similar patterns were seen when comparisons between
diastolic and systolic blood pressures were done within
the subpopulations. A detailed interpretation of these
differences is very complex, but generally the analysis
showed that different SNPs, genes or subnetworks are of
importance in discerning hypertensive from non-hyper-
tensive, between different hypertensive subpopulations,
and between diastolic and systolic blood pressures.
Thus, the entire population consisted of at least 14 sub-
populations that differed in importance of their
components.
For diastolic blood pressure the centrality indices for
ACER1 and SKHKAP were the most important in sub-
population 14 (see Additional file 15). Most remarkable
was, however, GCLM which turned out to be the central
node in many of the subpopulations. GCLM is a regula-
tor of GCLC in the glutathion metabolism in response
to oxidative stress [44], but is itself devoid of catalytic
activity. GCLM was the central node in three of the
four subpopulations with large genetic values (subpopu-
lations 1, 4, and 12), the exception being subpopulation
14 in which ACER1 presented itself with highest cen-
tralities. In contrast, for systolic blood pressure generally
the most important nodes were those in the kernel of
sphingosine-1-phosphate metabolism (ASAH1, SPHK1,
SPHKAP, and SGPP2). The subpopulations differed
somewhat in importance of these genes, but short of a
few additions (see Additional file 16), the regulation of
the systolic blood pressure was linked to this subnet-
work of the rheostat.
The basic biochemical network of the rheostat is
shown in Figure 4, a merger of all the networks of the
subpopulations is shown inF i g u r e5 ,a n dt h en e t w o r k
remaining after extraction of the former from the latter
is shown in Figure 6. Excluding pathway-direct regula-
tory intermediates in the sphingolipid metabolism the
latter network heuristically could be interpreted as
representing a superimposed regulatory network of the
sphingolipid metabolism. The epistatic links of the
superimposed regulatory network accounted for 83% of
all the links in the Supine model.
Fenger et al. BMC Genetics 2011, 12:44
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This study establishs the ceramide/sphingosine-1-phos-
phate rheostat network to have substantial influence on
blood pressure regulation. The approach presented iden-
tified the components of the rheostat network, but the
exact definition of the core structure of the rheostat was
hampered by a layer of interactions, which may be inter-
preted as regulatory structure keeping the rheostat
(tightly) controlled. Nevertheless, it was possible to pin-
point central components of the composite network,
regardless if the component are located in the core bio-
chemical rheostat network per se or are parts of regula-
tory structures. The network is much more complex
than indicated by the consensus biochemical pathways,
for the simple reason that epistasis introduced as links
in the network includes all kinds of interactions, not
just the rather simple directed biochemical pathways
(metabolic flux). It has been argued that correlation
between nodes may decrease exponentially with distance
and in large networks only nearest neighbour interac-
tions are actually observable [45], but obviously this is
not the case here. Regulatory structures encompass the
level of feedback mechanisms in the biochemical path-
ways beyond direct metabolic fluxes including dynamic
changes of cellular membranes caused by the composi-
tion of the sphingolipids in membranes [46], possible
regulatory functions of metabolic intermediates, spatial
organization and interaction of the components of the
rheostat, as well as regulation of transcriptional activity
and integration, all of which we have increasing but still
fragmentary knowledge about. This complexity is shown
in Figures 4-6. It should be noted that the networks
shown were strictly curetted only including the maximal
interactions between the nodes in each subpopulation.
The number of interactions are much larger (almost
700) and non-redundant as different SNPs interact in
different combinations with different relative epistatic
variance in different subpopulations.
The results suggests that 1) the fatty acid components
of the ceramides are not synthesized locally, but are
derived from external sources (extensive involvement of
FFAR1, tiny involvement of ELOV3); 2) only a restricted
number of ceramide analogous are of general impor-
tance (CerS1 and CerS6 are not captured in most sub-
population); and 3) the regulatory structures differs
between diastolic and systolic blood pressure, the former
related to the oxidative stress status and the latter to the
state of phosphorylation of sphingosine. It has recently
Figure 4 The core biochemical network of the ceramide/sphingosine-1-phosphate rheostat. A comprehensive core network is depicted
including the possible source of free fatty acids synthesized de novo in the vascular bed (the fatty acid elongation enzyme, ELOV3), as well as
the oxidative-redox system (GCLC and GCLM) which regulates neutral sphingomyelinase activity, a source of ceramides. These latter are only
introduced as “summary” variables as the focus has been on the de novo pathway of ceramide synthesis. Node degrees are shown in the
brackets.
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Page 14 of 18Figure 5 The networks constructed for all the subpopulations in the Supine model are merged including the interactions with
maximal genetic values producing the network shown. This network compiles all detected interactions including the core metabolic
network as shown in Figure 4 as well as indirect interactions.
Figure 6 Subtracting the core network in Figure 4 from the complexed network in Figure 5 generate a network of epistasis excluding
the metabolic flux.
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are influenced by the oxidative status of the cell includ-
ing sphingomyelinases [47-49]. These are of course just
summary statements and it is clear that all the subpopu-
lations differ in importance of the components in the
network and not the least their impact of the rheostat
on blood pressure regulation. Finally, as no SNP exclu-
sively defined any subpopulation this would suggest that
the phenotypic variation is mediated by a network of
genetic variations rather than a mutation in a single
gene [32,50], i.e. the blood pressure regulation is truly
polygenic. This statement is supported by the modest
results of the many large genome wide studies of single-
gene effects as mentioned in the Background and as
demonstrated in this report.
This study has been focussed on the de novo pathway
of ceramide synthesis, but the source of free fatty acid
were touch upon by including genes representing import
and de novo synthesis of free fatty acids, respectively.
Also genes regulating the generation of ceramides from
sphingomyelin were included, but were not evaluated in
d e t a i l .N e v e r t h e l e s s ,i tt u r n so u tt h a tt h ede novo path-
way may be the most important source of ceramides
considering the high relative genetic variance in the
hypertensive subpopulation 14. But it is clear that sup-
ply of ceramide from hydrolysis of sphingomyelin is of
significance, suggested by the strong involvement of
GCLM-GCLC, which regulates (among other processes)
the activity of the sphingomyelinases [51]. This has to
be elucidated by extending the approach to include all
candidate genes in the network.
The main interest in this study has been on the cera-
mide/sphingosine-1-phosphate network, but the genetic
influence was only substantial in four of the subpopula-
tions for the rheostat. Other networks (probably con-
nected to the rheostat) are operating and it must be
envisioned that many more subtypes of blood pressure
regulation and hypertension are present beyond those
identified in this study. Nevertheless, a genetic-metabolic
network is identified as a target for intervention in up to
10% of individuals with essential hypertension, which,
when confirmed and exact points of intervention are
identified, represent a substantial increase in patients
which potentially could benefit from personalized thera-
peutic intervention. In fact, the number of patients with
a clear deviation from normal physiology would be
tripled.
The approach presented here and that presented pre-
viously for diabetes mellitus type 2 [17] are the same,
but differ in the selection of genes in the analysis. In the
present presentation an established metabolic network
was analysed, while in the diabetes study several see-
mingly unrelated genes associated with diabetes detected
in numerous independent studies were included. In the
latter study almost no main effect could however be
detected in that particular population, but partitioning
the population and analysis of variance revealed the
importance of epistasis to the same degree as shown in
the present study. This lends support to the notion that
solitary detection of single-SNP associations with a con-
dition may be of real significance although they mostly
cannot be confirmed in different populations [52]. Both
of the studies stress the importance of modelling physio-
logical variables and in particular including general
populations and avoiding dichotomizing variables (or
rely on clinical endpoints) as they notoriously lose infor-
mation [53]. As shown here and in the diabetes study
[17] the use of continuous variables to partition of a
random selected study population into several subpopu-
lations provides far more information than is usually
obtained by dichotomizing variables as done in a case-
control study. This is true particular for polygenic con-
ditions such as hypertension and diabetes, as everybody
has a blood pressure and consume glucose only that
some deviates from a healthy state in these processes.
This probably also holds for most of the so-called Men-
delian or monogenic conditions, because the penetrance
is often not perfect, i.e. even such powerful “monogenes”
depends on the state (genotype) of the genes in the net-
work they are a part of.
Conclusions
The approach presented in this study could potentially
identify all the networks involved in the regulation of
the blood pressure when extended to the entire genome.
The latter is most desirable considering large fraction of
interactions detected beyond the core biochemical net-
work, which is merely a candidate gene approach with
local interactions that will not capture essential regula-
tory structures or components such as transcription fac-
tors or miRNA. Genome-wide genotyping with suitably
distributed SNPs should be very fruitful in the approach
presented here. The approach should be efficient in
detecting the network of genes of importance in any
polygenic condition or trait provided that essential phe-
notypic variables are available.
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